Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:EC 2.4.* (glycosyltransferase) inhibitor
go back to main search page
Accession:CHEBI:76662 term browser browse the term
Definition:A transferase inhibitor inhibiting the action of a glycosyltransferase (EC 2.4.*.*).
Synonyms:related_synonym: EC 2.4.* inhibitor;   EC 2.4.* inhibitors;   glycosyltransferase (EC 2.4.*) inhibitors;   glycosyltransferase inhibitor;   glycosyltransferase inhibitors



show annotations for term's descendants           Sort by:
 
1-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
JBrowse link
G Dek DEK proto-oncogene decreases chemical synthesis ISO DEK protein results in decreased chemical synthesis of N(1)-methylnicotinamide CTD PMID:28558019 NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
JBrowse link
G Lepr leptin receptor affects abundance ISO LEPR affects the abundance of N(1)-methylnicotinamide CTD PMID:20567778 NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA] CTD PMID:32298659 NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression EXP N(1)-methylnicotinamide results in increased expression of PTGS2 mRNA CTD PMID:18385449 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Retn resistin multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of RETN mRNA] CTD PMID:32298659 NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
JBrowse link
G Slc22a1 solute carrier family 22 member 1 increases import ISO SLC22A1 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
JBrowse link
G Slc22a16 solute carrier family 22 member 16 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium] CTD PMID:15963465 NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019
JBrowse link
G Slc22a2 solute carrier family 22 member 2 increases import ISO SLC22A2 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
JBrowse link
G Slc22a3 solute carrier family 22 member 3 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] CTD PMID:10966924 NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
JBrowse link
3-aminobenzamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions ISO 3-aminobenzamide promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]
3-aminobenzamide promotes the reaction [Alitretinoin promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]]; 3-aminobenzamide promotes the reaction [Alitretinoin results in increased expression of ABCA1 mRNA]; 3-aminobenzamide promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]
CTD PMID:27026705 NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases expression EXP
ISO
3-aminobenzamide results in increased expression of ADIPOQ mRNA CTD PMID:18815186 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Adipor1 adiponectin receptor 1 increases expression ISO
EXP
3-aminobenzamide results in increased expression of ADIPOR1 mRNA CTD PMID:18815186 NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241
JBrowse link
G Adipor2 adiponectin receptor 2 increases expression EXP
ISO
3-aminobenzamide results in increased expression of ADIPOR2 mRNA CTD PMID:18815186 NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
JBrowse link
G Atm ATM serine/threonine kinase multiple interactions ISO 3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of ATM protein] CTD PMID:22226932 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
JBrowse link
G Bglap bone gamma-carboxyglutamate protein increases expression ISO 3-aminobenzamide results in increased expression of BGLAP mRNA CTD PMID:15670817 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
JBrowse link
G Casp3 caspase 3 multiple interactions EXP
ISO
3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; 3-aminobenzamide inhibits the reaction [SFRP1 protein promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]
3-aminobenzamide inhibits the reaction [[oxyhyponitrite results in increased abundance of nitroxyl] which results in increased activity of CASP3 protein]
CTD PMID:11744336 PMID:16505238 PMID:30377735 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions EXP 3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein] CTD PMID:16505238 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Ccnd1 cyclin D1 decreases expression ISO 3-aminobenzamide results in decreased expression of CCND1 mRNA CTD PMID:15670817 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Cd36 CD36 molecule increases expression EXP 3-aminobenzamide results in increased expression of CD36 mRNA CTD PMID:18815186 NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO 3-aminobenzamide results in increased expression of CDKN1A mRNA CTD PMID:15670817 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Ctnnb1 catenin beta 1 decreases expression ISO 3-aminobenzamide results in decreased expression of CTNNB1 mRNA CTD PMID:15670817 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO 3-aminobenzamide inhibits the reaction [Bleomycin results in increased secretion of CXCL2 protein] CTD PMID:26600069 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO 3-aminobenzamide promotes the reaction [RB1 protein binds to E2F1 protein] CTD PMID:15670817 NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
JBrowse link
G Ep300 E1A binding protein p300 multiple interactions EXP 3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of EP300 mRNA] CTD PMID:22228707 NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088
JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
decreases expression
ISO
EXP
3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 protein]
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of ERCC1 mRNA]
3-aminobenzamide results in decreased expression of ERCC1 mRNA; 3-aminobenzamide results in decreased expression of ERCC1 protein
CTD PMID:22228707 NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit multiple interactions
decreases expression
ISO
EXP
3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 protein]
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of ERCC4 mRNA]
3-aminobenzamide results in decreased expression of ERCC4 mRNA; 3-aminobenzamide results in decreased expression of ERCC4 protein
CTD PMID:22228707 NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions
affects response to substance
ISO 3-aminobenzamide inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]
ERCC6 gene mutant form affects the susceptibility to 3-aminobenzamide
CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
G Fn1 fibronectin 1 multiple interactions
decreases expression
ISO
EXP
3-aminobenzamide inhibits the reaction [Glucose results in increased expression of FN1 mRNA]
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of FN1 mRNA]
3-aminobenzamide results in decreased expression of FN1 protein
CTD PMID:22228707 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO 3-aminobenzamide inhibits the reaction [hydroquinone results in increased expression of HRAS protein] CTD PMID:26047893 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
JBrowse link
G Id2 inhibitor of DNA binding 2 decreases expression ISO 3-aminobenzamide results in decreased expression of ID2 mRNA CTD PMID:15670817 NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA] CTD PMID:19962977 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Ins2 insulin 2 multiple interactions ISO 3-aminobenzamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of INS protein] CTD PMID:16505238 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit decreases expression ISO 3-aminobenzamide results in decreased expression of JUN mRNA CTD PMID:15670817 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Lep leptin increases expression EXP 3-aminobenzamide results in increased expression of LEP mRNA CTD PMID:18815186 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
JBrowse link
G Lpl lipoprotein lipase increases expression EXP 3-aminobenzamide results in increased expression of LPL mRNA CTD PMID:18815186 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
JBrowse link
G Mafa MAF bZIP transcription factor A multiple interactions ISO
EXP
3-aminobenzamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]
3-aminobenzamide inhibits the reaction [Glucose results in decreased expression of MAFA mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in decreased expression of MAFA protein]
CTD PMID:16505238 NCBI chr 7:107,432,292...107,435,061
Ensembl chr 7:107,433,605...107,434,690
JBrowse link
G Mir126b microRNA 126b decreases expression
multiple interactions
ISO 3-aminobenzamide results in decreased expression of MIR126 mRNA
3-aminobenzamide inhibits the reaction [Asbestos, Crocidolite results in increased expression of MIR126 mRNA]; [Decitabine co-treated with 3-aminobenzamide] inhibits the reaction [Asbestos, Crocidolite results in increased expression of MIR126 mRNA]
CTD PMID:32006662 NCBI chr 3:9,415,087...9,415,159 JBrowse link
G Mpo myeloperoxidase multiple interactions ISO 3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of MPO protein] CTD PMID:19962977 NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO 3-aminobenzamide results in decreased expression of MYC mRNA CTD PMID:15670817 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO 3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NFKBIA mRNA] CTD PMID:19962977 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 decreases ADP-ribosylation ISO 3-aminobenzamide results in decreased ADP-ribosylation of NR1H3 protein CTD PMID:27026705 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases activity
ISO
EXP
3-aminobenzamide inhibits the reaction [Asbestos, Amosite results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Asbestos, Crocidolite results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Benzoyl Peroxide results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Capsaicin results in increased ADP-ribosylation of PARP1 protein modified form]; 3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [hydroquinone results in increased expression of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Lithocholic Acid analog results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [mezerein results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [PARP1 protein results in increased susceptibility to [Potassium Dichromate co-treated with nickel sulfate]]; 3-aminobenzamide inhibits the reaction [Smoke analog results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of PARP1 protein]; 3-aminobenzamide promotes the reaction [Capsaicin results in increased cleavage of and results in increased activity of PARP1 protein]; 3-aminobenzamide promotes the reaction [Capsaicin results in increased expression of PARP1 protein]; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [3-aminobenzamide results in decreased activity of PARP1 protein] which results in increased susceptibility to Cisplatin
3-aminobenzamide inhibits the reaction [[sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in increased cleavage of PARP1 protein]; 3-aminobenzamide inhibits the reaction [sodium arsenite results in increased cleavage of PARP1 protein]
3-aminobenzamide inhibits the reaction [PARP1 protein results in increased susceptibility to Acetaminophen]
CTD PMID:2120135 PMID:2126186 PMID:11217149 PMID:15075382 PMID:15601672 More... NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Parp2 poly (ADP-ribose) polymerase 2 affects binding ISO PARP2 protein binds to 3-aminobenzamide CTD PMID:20092359 NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
JBrowse link
G Pcna proliferating cell nuclear antigen increases expression EXP 3-aminobenzamide results in increased expression of PCNA protein CTD PMID:11049868 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Pdx1 pancreatic and duodenal homeobox 1 multiple interactions EXP 3-aminobenzamide inhibits the reaction [Palmitic Acid results in decreased expression of PDX1 protein] CTD PMID:19513971 NCBI chr12:7,757,865...7,763,064
Ensembl chr12:7,757,865...7,763,064
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases activity
multiple interactions
decreases ADP-ribosylation
EXP 3-aminobenzamide results in increased activity of PPARG protein
3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein]
3-aminobenzamide results in decreased ADP-ribosylation of PPARG protein
CTD PMID:18815186 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Prkdc protein kinase, DNA-activated, catalytic subunit multiple interactions ISO 3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of PRKDC protein] CTD PMID:22226932 NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO 3-aminobenzamide promotes the reaction [RB1 protein binds to E2F1 protein]; 3-aminobenzamide results in decreased phosphorylation of and results in increased activity of RB1 protein CTD PMID:15670817 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP 3-aminobenzamide inhibits the reaction [Methylnitrosourea results in decreased expression of RELA protein modified form] CTD PMID:17137578 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Sfrp1 secreted frizzled-related protein 1 multiple interactions EXP 3-aminobenzamide inhibits the reaction [SFRP1 protein promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]] CTD PMID:30377735 NCBI chr16:68,575,763...68,613,905
Ensembl chr16:68,575,763...68,614,286
JBrowse link
G Spp1 secreted phosphoprotein 1 increases expression ISO 3-aminobenzamide results in increased expression of SPP1 mRNA CTD PMID:15670817 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
JBrowse link
G Stk11 serine/threonine kinase 11 multiple interactions ISO 3-aminobenzamide inhibits the reaction [resveratrol results in increased phosphorylation of STK11 protein] CTD PMID:19620254 NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
JBrowse link
G Tert telomerase reverse transcriptase multiple interactions ISO 3-aminobenzamide inhibits the reaction [TERT protein mutant form results in decreased susceptibility to temozolomide] CTD PMID:12488552 NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO 3-aminobenzamide inhibits the reaction [Capsaicin results in increased expression of TP53 protein]; 3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein] CTD PMID:22226932 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
8-azaguanine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mapt microtubule-associated protein tau decreases expression ISO Azaguanine results in decreased expression of MAPT protein CTD PMID:16930453 NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
JBrowse link
aztreonam term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO Aztreonam results in increased expression of ABCC2 mRNA CTD PMID:24657338 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 increases expression ISO Aztreonam results in increased expression of ABCG5 mRNA CTD PMID:24657338 NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 increases expression ISO Aztreonam results in increased expression of ABCG8 mRNA CTD PMID:24657338 NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
JBrowse link
G Npc1l1 NPC1 like intracellular cholesterol transporter 1 decreases expression ISO Aztreonam results in decreased expression of NPC1L1 mRNA CTD PMID:24657338 NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
JBrowse link
G Nr5a2 nuclear receptor subfamily 5, group A, member 2 increases expression ISO Aztreonam results in increased expression of NR5A2 mRNA CTD PMID:24657338 NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
JBrowse link
G RT1-Ha RT1 class II, locus Ha affects expression ISO Aztreonam affects the expression of HLA-DPA1 mRNA CTD PMID:25811541 NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,760,118...4,770,244
JBrowse link
G Slc10a1 solute carrier family 10 member 1 increases expression ISO Aztreonam results in increased expression of SLC10A1 mRNA CTD PMID:24657338 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
JBrowse link
G Slc10a2 solute carrier family 10 member 2 decreases expression ISO Aztreonam results in decreased expression of SLC10A2 mRNA CTD PMID:24657338 NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
JBrowse link
G Slc51b solute carrier family 51 subunit beta decreases expression ISO Aztreonam results in decreased expression of SLC51B mRNA CTD PMID:24657338 NCBI chr 8:65,931,891...65,934,893
Ensembl chr 8:65,931,890...65,940,145
JBrowse link
ceftazidime pentahydrate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc4 ATP binding cassette subfamily C member 4 increases transport ISO ABCC4 protein results in increased transport of Ceftazidime CTD PMID:17939016 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
JBrowse link
G Dhfr dihydrofolate reductase decreases activity ISO Ceftazidime results in decreased activity of DHFR protein CTD PMID:25418905 NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
JBrowse link
G Hsf1 heat shock transcription factor 1 decreases activity ISO Ceftazidime results in decreased activity of HSF1 protein CTD PMID:34170685 NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
JBrowse link
G Il10 interleukin 10 multiple interactions ISO Ceftazidime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] CTD PMID:16939481 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
corilagin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cat catalase multiple interactions EXP corilagin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] CTD PMID:30582900 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions EXP corilagin inhibits the reaction [1-naphthyl isothiocyanate decreases expression of nr1h4 mRNA and protein in rat liver]; corilagin increases expression of nr1h4 mRNA and protein in rat embryonic liver cells RGD PMID:29235094 RGD:15042872 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
JBrowse link
G Tnf tumor necrosis factor decreases secretion ISO corilagin results in decreased secretion of TNF protein CTD PMID:12628509 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
didanosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alb albumin affects binding ISO Didanosine binds to ALB protein CTD PMID:15814459 PMID:16336266 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Hfe homeostatic iron regulator multiple interactions ISO HFE gene SNP affects the susceptibility to [Didanosine co-treated with Stavudine] CTD PMID:16847405 NCBI chr17:41,413,451...41,421,502
Ensembl chr17:41,413,451...41,421,502
JBrowse link
G Il24 interleukin 24 decreases expression ISO Didanosine results in decreased expression of IL24 mRNA CTD PMID:32816093 NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
JBrowse link
G Mt-co2 mitochondrially encoded cytochrome c oxidase II decreases expression
multiple interactions
ISO Didanosine results in decreased expression of COX2 mRNA
tenofovir promotes the reaction [Didanosine results in decreased expression of COX2 mRNA]
CTD PMID:16940060 NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
JBrowse link
G Slc29a3 solute carrier family 29 member 3 affects transport ISO SLC29A3 protein affects the transport of Didanosine CTD PMID:19164483 NCBI chr20:28,645,265...28,685,388
Ensembl chr20:28,647,391...28,685,388
JBrowse link
G Slpi secretory leukocyte peptidase inhibitor increases expression ISO Didanosine results in increased expression of SLPI mRNA CTD PMID:32816093 NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
JBrowse link
eliglustat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gba glucosylceramidase beta multiple interactions ISO eliglustat results in decreased activity of and affects the localization of GBA protein CTD PMID:21250698 NCBI chr 2:174,609,437...174,615,457
Ensembl chr 2:174,609,403...174,618,263
JBrowse link
ellagic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acp3 acid phosphatase 3 increases expression ISO Ellagic Acid results in increased expression of ACP3 mRNA CTD PMID:12002526 NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant multiple interactions ISO Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] CTD PMID:32971123 NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 increases expression ISO Ellagic Acid results in increased expression of AIFM1 protein CTD PMID:23554011 NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256
JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation ISO Ellagic Acid results in increased phosphorylation of AKT1 protein CTD PMID:26986492 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Alb albumin multiple interactions
affects binding
ISO ALB protein promotes the reaction [Ellagic Acid results in increased activity of F12 protein]
Ellagic Acid binds to ALB protein
CTD PMID:6343536 PMID:25247703 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Alkbh2 alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase decreases activity ISO Ellagic Acid results in decreased activity of ALKBH2 protein CTD PMID:31088072 NCBI chr12:42,494,187...42,500,929
Ensembl chr12:42,496,300...42,500,914
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 decreases expression ISO Ellagic Acid results in decreased expression of APAF1 mRNA CTD PMID:12002526 NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
JBrowse link
G Ascl1 achaete-scute family bHLH transcription factor 1 increases expression ISO Ellagic Acid results in increased expression of ASCL1 mRNA CTD PMID:12002526 NCBI chr 7:21,904,153...21,906,003
Ensembl chr 7:21,903,126...21,905,993
JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) increases expression ISO Ellagic Acid results in increased expression of ASNS mRNA CTD PMID:12002526 NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
JBrowse link
G Atf3 activating transcription factor 3 increases expression ISO Ellagic Acid results in increased expression of ATF3 mRNA CTD PMID:12002526 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
JBrowse link
G Atg5 autophagy related 5 increases expression ISO Ellagic Acid results in increased expression of ATG5 mRNA CTD PMID:12002526 NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
JBrowse link
G Bad BCL2-associated agonist of cell death increases expression ISO Ellagic Acid results in increased expression of BAD protein CTD PMID:23554011 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of BAX mRNA] CTD PMID:29854611 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression
multiple interactions
ISO
EXP
Ellagic Acid results in increased expression of BCL2 protein
Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of BCL2 mRNA]
[Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]
CTD PMID:20103723 PMID:22386815 PMID:29854611 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Bmp6 bone morphogenetic protein 6 decreases expression ISO Ellagic Acid results in decreased expression of BMP6 mRNA CTD PMID:12002526 NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
JBrowse link
G Brf1 BRF1, RNA polymerase III transcription initiation factor subunit decreases expression ISO Ellagic Acid results in decreased expression of BRF1 mRNA CTD PMID:12002526 NCBI chr 6:132,034,380...132,081,296
Ensembl chr 6:132,037,272...132,081,278
JBrowse link
G Calr calreticulin decreases expression ISO Ellagic Acid results in decreased expression of CALR mRNA CTD PMID:12002526 NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
JBrowse link
G Casp3 caspase 3 increases expression
multiple interactions
increases activity
decreases activity
decreases expression
ISO
EXP
Ellagic Acid results in increased expression of CASP3 mRNA
Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased activity of CASP3 protein]
Ellagic Acid results in increased expression of and results in increased activity of CASP3 protein
Ellagic Acid results in increased activity of CASP3 protein
Ellagic Acid results in decreased activity of CASP3 protein
Ellagic Acid results in decreased expression of CASP3 mRNA
CTD PMID:12002526 PMID:22386815 PMID:23554011 PMID:23811531 PMID:28815802 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions ISO Ellagic Acid results in increased expression of and results in increased activity of CASP9 protein CTD PMID:23554011 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cat catalase increases activity
multiple interactions
EXP Ellagic Acid results in increased activity of CAT protein
Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]
CTD PMID:20074268 PMID:24877639 PMID:29864931 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases secretion ISO Ellagic Acid results in decreased secretion of CCL2 protein CTD PMID:20816778 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccng1 cyclin G1 decreases expression EXP ellagic acid inhibits the reaction [estrogen increases expression of Ccng1 mRNA and protein in rat mammary tissue] RGD PMID:23791885 RGD:151356928 NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
JBrowse link
G Cd14 CD14 molecule decreases expression ISO Ellagic Acid results in decreased expression of CD14 mRNA CTD PMID:20816778 NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression ISO Ellagic Acid results in decreased expression of CDK1 protein CTD PMID:23554011 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
ISO [resveratrol co-treated with Ellagic Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA]
[Ellagic Acid co-treated with Quercetin] results in increased expression of CDKN1A mRNA; Ellagic Acid promotes the reaction [Quercetin results in increased expression of CDKN1A protein]; pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased expression of CDKN1A protein]]
Ellagic Acid results in increased expression of CDKN1A protein
CTD PMID:15735102 PMID:20103723 PMID:23554011 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Ctsd cathepsin D multiple interactions EXP Ellagic Acid inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] CTD PMID:21762681 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
JBrowse link
G Ctsk cathepsin K multiple interactions ISO Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK protein] CTD PMID:32971123 NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases expression
decreases activity
ISO Ellagic Acid results in decreased expression of CYP1A1 mRNA
Ellagic Acid results in decreased activity of CYP1A1 protein
CTD PMID:19329757 PMID:20816778 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity
multiple interactions
ISO Ellagic Acid results in decreased activity of CYP1B1 protein
[Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]
CTD PMID:19329757 PMID:20103723 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Daxx death-domain associated protein decreases expression ISO Ellagic Acid results in decreased expression of DAXX mRNA CTD PMID:12002526 NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843
JBrowse link
G Dffa DNA fragmentation factor subunit alpha decreases expression ISO Ellagic Acid results in decreased expression of DFFA mRNA CTD PMID:12002526 NCBI chr 5:159,540,718...159,553,639
Ensembl chr 5:159,540,715...159,553,633
JBrowse link
G E4f1 E4F transcription factor 1 increases expression ISO Ellagic Acid results in increased expression of E4F1 mRNA CTD PMID:12002526 NCBI chr10:13,471,478...13,495,018
Ensembl chr10:13,474,456...13,485,974
JBrowse link
G Egr3 early growth response 3 decreases expression ISO Ellagic Acid results in decreased expression of EGR3 mRNA CTD PMID:12002526 NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627
JBrowse link
G Endog endonuclease G increases expression ISO Ellagic Acid results in increased expression of ENDOG protein CTD PMID:23554011 NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932
JBrowse link
G Ep300 E1A binding protein p300 increases expression ISO Ellagic Acid results in increased expression of EP300 mRNA CTD PMID:12002526 NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088
JBrowse link
G Eps15 epidermal growth factor receptor pathway substrate 15 increases expression ISO Ellagic Acid results in increased expression of EPS15 mRNA CTD PMID:12002526 NCBI chr 5:124,045,865...124,146,221
Ensembl chr 5:124,045,926...124,146,221
JBrowse link
G Ezh1 enhancer of zeste 1 polycomb repressive complex 2 subunit increases expression ISO Ellagic Acid results in increased expression of EZH1 mRNA CTD PMID:12002526 NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921
JBrowse link
G F12 coagulation factor XII multiple interactions
increases activity
ISO ALB protein promotes the reaction [Ellagic Acid results in increased activity of F12 protein] CTD PMID:6343536 NCBI chr17:9,207,683...9,215,530
Ensembl chr17:9,207,683...9,215,530
JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 decreases expression ISO Ellagic Acid results in decreased expression of FGFR1 mRNA CTD PMID:12002526 NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
JBrowse link
G Flna filamin A decreases expression ISO Ellagic Acid results in decreased expression of FLNA mRNA CTD PMID:12002526 NCBI chr  X:152,007,758...152,034,266
Ensembl chr  X:152,007,758...152,031,052
JBrowse link
G Fn1 fibronectin 1 multiple interactions EXP Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FN1 protein] CTD PMID:24877639 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; [Ellagic Acid co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein] CTD PMID:20103723 PMID:32971123 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase decreases activity ISO Ellagic Acid results in decreased activity of G6PD protein CTD PMID:25130191 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801
JBrowse link
G Gal galanin and GMAP prepropeptide multiple interactions EXP Ellagic Acid inhibits the reaction [phosalone results in increased activity of GAL protein] CTD PMID:27965107 NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
JBrowse link
G Gpld1 glycosylphosphatidylinositol specific phospholipase D1 decreases expression ISO Ellagic Acid results in decreased expression of GPLD1 mRNA CTD PMID:12002526 NCBI chr17:40,084,427...40,132,035
Ensembl chr17:40,084,617...40,126,939
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of GPT protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of GPT protein] CTD PMID:24877639 PMID:29935397 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Gpx1 glutathione peroxidase 1 multiple interactions EXP Ellagic Acid inhibits the reaction [sodium arsenite results in decreased expression of GPX1 mRNA] CTD PMID:29935397 NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased activity of GSR protein] CTD PMID:24877639 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Gsta4 glutathione S-transferase alpha 4 increases expression ISO Ellagic Acid results in increased expression of GSTA4 mRNA CTD PMID:12002526 NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
JBrowse link
G Gstt1 glutathione S-transferase theta 1 affects expression EXP Ellagic Acid affects the expression of GSTT1 protein CTD PMID:9855024 NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
JBrowse link
G Gtf2e2 general transcription factor IIE subunit 2 increases expression ISO Ellagic Acid results in increased expression of GTF2E2 mRNA CTD PMID:12002526 NCBI chr16:58,399,307...58,449,467
Ensembl chr16:58,399,107...58,449,371
JBrowse link
G Gtf2h4 general transcription factor 2H subunit 4 increases expression ISO Ellagic Acid results in increased expression of GTF2H4 mRNA CTD PMID:12002526 NCBI chr20:3,071,328...3,076,990
Ensembl chr20:3,071,328...3,076,984
JBrowse link
G Gusb glucuronidase, beta multiple interactions EXP Ellagic Acid inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] CTD PMID:21762681 NCBI chr12:26,701,191...26,714,718
Ensembl chr12:26,697,951...26,726,905
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha decreases expression ISO Ellagic Acid results in decreased expression of HIF1A mRNA CTD PMID:12002526 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
JBrowse link
G Hlcs holocarboxylase synthetase decreases activity ISO Ellagic Acid results in decreased activity of HLCS protein CTD PMID:26303405 NCBI chr11:33,455,806...33,635,197
Ensembl chr11:33,455,809...33,624,222
JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions
ISO Ellagic Acid results in increased expression of HMOX1 mRNA; Ellagic Acid results in increased expression of HMOX1 protein
[Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 mRNA; [Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 protein
CTD PMID:22386815 PMID:23546295 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO [Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene]; [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene] CTD PMID:20103723 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
JBrowse link
G Ier2 immediate early response 2 increases expression ISO Ellagic Acid results in increased expression of IER2 mRNA CTD PMID:12002526 NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211
JBrowse link
G Ifng interferon gamma multiple interactions EXP Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IFNG mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IFNG protein] CTD PMID:29854611 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Igfbp2 insulin-like growth factor binding protein 2 increases expression ISO Ellagic Acid results in increased expression of IGFBP2 mRNA CTD PMID:12002526 NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
JBrowse link
G Igfbp4 insulin-like growth factor binding protein 4 decreases expression ISO Ellagic Acid results in decreased expression of IGFBP4 mRNA CTD PMID:12002526 NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
JBrowse link
G Il1b interleukin 1 beta decreases expression
multiple interactions
ISO
EXP
Ellagic Acid results in decreased expression of IL1B mRNA
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IL1B mRNA]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of IL1B protein]
Ellagic Acid inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]
CTD PMID:18377686 PMID:20816778 PMID:21762681 PMID:24877639 PMID:27965107 More... NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il1r1 interleukin 1 receptor type 1 decreases expression ISO Ellagic Acid results in decreased expression of IL1R1 mRNA CTD PMID:20816778 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
JBrowse link
G Il6 interleukin 6 multiple interactions EXP Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IL6 protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL6 protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of IL6 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL6 protein] CTD PMID:21762681 PMID:24877639 PMID:27965107 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Inpp5d inositol polyphosphate-5-phosphatase D increases expression ISO Ellagic Acid results in increased expression of INPP5D mRNA CTD PMID:12002526 NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746
JBrowse link
G Iqgap2 IQ motif containing GTPase activating protein 2 increases expression ISO Ellagic Acid results in increased expression of IQGAP2 mRNA CTD PMID:12002526 NCBI chr 2:26,894,836...27,170,270
Ensembl chr 2:26,894,825...27,170,279
JBrowse link
G Irf9 interferon regulatory factor 9 increases expression ISO Ellagic Acid results in increased expression of IRF9 mRNA CTD PMID:12002526 NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit decreases expression ISO Ellagic Acid results in decreased expression of JUN mRNA; Ellagic Acid results in decreased expression of JUN protein modified form CTD PMID:23811531 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Litaf lipopolysaccharide-induced TNF factor increases expression ISO Ellagic Acid results in increased expression of LITAF mRNA CTD PMID:12002526 NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
JBrowse link
G Map1a microtubule-associated protein 1A decreases expression ISO Ellagic Acid results in decreased expression of MAP1A mRNA CTD PMID:12002526 NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899
JBrowse link
G Map3k1 mitogen-activated protein kinase kinase kinase 1 decreases expression ISO Ellagic Acid results in decreased expression of MAP3K1 mRNA; Ellagic Acid results in decreased expression of MAP3K1 protein CTD PMID:23811531 NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein] CTD PMID:32971123 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk11 mitogen-activated protein kinase 11 increases expression ISO Ellagic Acid results in increased expression of MAPK11 mRNA CTD PMID:23811531 NCBI chr 7:120,218,471...120,225,488
Ensembl chr 7:120,218,478...120,225,395
JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions EXP Ellagic Acid inhibits the reaction [phosalone results in increased expression of MAPK14 protein] CTD PMID:27965107 NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein] CTD PMID:32971123 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO [Ellagic Acid co-treated with Quercetin] results in increased phosphorylation of MAPK8 protein CTD PMID:15735102 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO [Ellagic Acid co-treated with Quercetin] results in increased phosphorylation of MAPK9 protein CTD PMID:15735102 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
JBrowse link
G Mgst1 microsomal glutathione S-transferase 1 decreases activity EXP Ellagic Acid results in decreased activity of MGST1 protein CTD PMID:16125204 NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
JBrowse link
G Mmd monocyte to macrophage differentiation-associated increases expression ISO Ellagic Acid results in increased expression of MMD mRNA CTD PMID:12002526 NCBI chr10:75,073,278...75,101,528
Ensembl chr10:75,073,365...75,101,528
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO Ellagic Acid results in decreased activity of and results in decreased secretion of MMP2 protein; zinc chloride inhibits the reaction [Ellagic Acid results in decreased activity of and results in decreased secretion of MMP2 protein] CTD PMID:21573219 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
JBrowse link
G Nfatc1 nuclear factor of activated T-cells 1 multiple interactions ISO Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein] CTD PMID:32971123 NCBI chr18:74,046,421...74,156,041
Ensembl chr18:74,046,904...74,156,028
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 affects localization
increases expression
multiple interactions
affects response to substance
ISO Ellagic Acid affects the localization of NFE2L2 protein
Ellagic Acid results in increased expression of NFE2L2 mRNA
Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of NFE2L2 mRNA]
[Paraquat co-treated with Ellagic Acid] results in increased expression of and affects the localization of NFE2L2 protein; [Paraquat co-treated with Ellagic Acid] results in increased expression of NFE2L2 mRNA; Ellagic Acid results in increased expression of and affects the localization of NFE2L2 protein
Ellagic Acid results in increased expression of NFE2L2 mRNA; Ellagic Acid results in increased expression of NFE2L2 protein
NFE2L2 protein affects the susceptibility to Ellagic Acid
CTD PMID:22386815 PMID:23546295 PMID:30503583 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkb2 nuclear factor kappa B subunit 2 decreases expression ISO Ellagic Acid results in decreased expression of NFKB2 mRNA CTD PMID:12002526 NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
JBrowse link
G Nnat neuronatin increases expression ISO Ellagic Acid results in increased expression of NNAT mRNA CTD PMID:12002526 NCBI chr 3:146,225,941...146,228,868
Ensembl chr 3:146,226,407...146,228,834
JBrowse link
G Nop56 NOP56 ribonucleoprotein decreases expression ISO Ellagic Acid results in decreased expression of NOP56 mRNA CTD PMID:12002526 NCBI chr 3:117,476,963...117,481,847
Ensembl chr 3:117,477,053...117,481,841
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein] CTD PMID:28815802 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Npas2 neuronal PAS domain protein 2 increases expression ISO Ellagic Acid results in increased expression of NPAS2 mRNA CTD PMID:12002526 NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression
multiple interactions
ISO Ellagic Acid results in increased expression of NQO1 mRNA; Ellagic Acid results in increased expression of NQO1 protein
[Paraquat co-treated with Ellagic Acid] results in increased expression of NQO1 mRNA; [Paraquat co-treated with Ellagic Acid] results in increased expression of NQO1 protein
CTD PMID:23546295 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases activity ISO Ellagic Acid results in increased activity of NR1I3 protein CTD PMID:21821919 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
JBrowse link
G Parg poly (ADP-ribose) glycohydrolase decreases activity ISO Ellagic Acid results in decreased activity of PARG protein CTD PMID:19840838 NCBI chr16:7,436,429...7,544,276
Ensembl chr16:7,436,476...7,544,273
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions EXP Ellagic Acid inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein] CTD PMID:25247703 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO [resveratrol co-treated with Ellagic Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCNA mRNA] CTD PMID:20103723 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Pdia2 protein disulfide isomerase family A, member 2 multiple interactions EXP Ellagic Acid inhibits the reaction [Rotenone results in increased nitrosation of and results in decreased activity of PDIA2 protein] CTD PMID:25247703 NCBI chr10:15,215,824...15,218,937
Ensembl chr10:15,215,824...15,220,931
JBrowse link
G Pgd phosphogluconate dehydrogenase decreases activity ISO Ellagic Acid results in decreased activity of PGD protein CTD PMID:25130191 NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
JBrowse link
G Pla2g2a phospholipase A2 group IIA decreases expression ISO Ellagic Acid results in decreased expression of PLA2G2A mRNA CTD PMID:20816778 NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
JBrowse link
G Plp2 proteolipid protein 2 increases expression ISO Ellagic Acid results in increased expression of PLP2 mRNA CTD PMID:12002526 NCBI chr  X:14,834,249...14,837,648
Ensembl chr  X:14,834,231...14,838,514
JBrowse link
G Pml PML nuclear body scaffold decreases expression ISO Ellagic Acid results in decreased expression of PML mRNA CTD PMID:12002526 NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
JBrowse link
G Ppard peroxisome proliferator-activated receptor delta decreases expression ISO Ellagic Acid results in decreased expression of PPARD mRNA CTD PMID:12002526 NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression ISO Ellagic Acid results in increased expression of PPARG protein CTD PMID:23811531 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions
decreases expression
ISO Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of PPARGC1A mRNA]
Ellagic Acid results in decreased expression of PPARGC1A mRNA
CTD PMID:30503583 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Prkg1 protein kinase cGMP-dependent 1 decreases expression ISO Ellagic Acid results in decreased expression of PRKG1 mRNA CTD PMID:12002526 NCBI chr 1:228,409,883...229,638,794
Ensembl chr 1:228,408,947...229,639,080
JBrowse link
G Ptn pleiotrophin decreases expression
increases expression
ISO Ellagic Acid results in decreased expression of PTN mRNA
Ellagic Acid results in increased expression of PTN mRNA
CTD PMID:12002526 NCBI chr 4:65,293,731...65,375,572
Ensembl chr 4:65,293,734...65,375,456
JBrowse link
G Ptprn2 protein tyrosine phosphatase, receptor type N2 increases expression ISO Ellagic Acid results in increased expression of PTPRN2 mRNA CTD PMID:12002526 NCBI chr 6:137,439,572...138,191,575
Ensembl chr 6:137,439,540...138,191,575
JBrowse link
G Ran RAN, member RAS oncogene family decreases expression ISO Ellagic Acid results in decreased expression of RAN mRNA CTD PMID:12002526 NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions EXP Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 protein] CTD PMID:27965107 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
JBrowse link
G Reck reversion-inducing-cysteine-rich protein with kazal motifs increases expression
multiple interactions
ISO Ellagic Acid results in increased expression of RECK mRNA; Ellagic Acid results in increased expression of RECK protein
zinc chloride inhibits the reaction [Ellagic Acid results in increased expression of RECK mRNA]; zinc chloride inhibits the reaction [Ellagic Acid results in increased expression of RECK protein]
CTD PMID:21573219 NCBI chr 5:58,102,915...58,169,513
Ensembl chr 5:58,102,981...58,169,502
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit decreases expression
multiple interactions
ISO
EXP
Ellagic Acid results in decreased expression of RELA mRNA
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein]
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of RELA protein]
CTD PMID:12002526 PMID:24877639 PMID:27965107 PMID:32971123 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Rgs5 regulator of G-protein signaling 5 decreases expression ISO Ellagic Acid results in decreased expression of RGS5 mRNA CTD PMID:12002526 NCBI chr13:81,848,254...81,885,053
Ensembl chr13:81,836,304...81,885,518
JBrowse link
G Scd stearoyl-CoA desaturase decreases expression ISO Ellagic Acid results in decreased expression of SCD mRNA CTD PMID:20816778 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
JBrowse link
G Septin2 septin 2 increases expression ISO Ellagic Acid results in increased expression of SEPTIN2 mRNA CTD PMID:12002526 NCBI chr 9:94,018,141...94,051,386
Ensembl chr 9:94,018,208...94,051,386
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions EXP Ellagic Acid inhibits the reaction [sodium arsenite results in decreased expression of SOD2 mRNA] CTD PMID:29935397 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Sod3 superoxide dismutase 3 decreases expression ISO Ellagic Acid results in decreased expression of SOD3 mRNA CTD PMID:12002526 NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC protein] CTD PMID:32971123 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
JBrowse link
G Star steroidogenic acute regulatory protein increases expression
multiple interactions
ISO Ellagic Acid results in increased expression of STAR mRNA
Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of STAR mRNA]
CTD PMID:30503583 NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
JBrowse link
G Stat3 signal transducer and activator of transcription 3 increases expression
decreases expression
ISO Ellagic Acid results in increased expression of STAT3 mRNA
Ellagic Acid results in decreased expression of STAT3 mRNA
CTD PMID:12002526 PMID:20816778 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
G Taf1c TATA-box binding protein associated factor, RNA polymerase 1 subunit C decreases expression ISO Ellagic Acid results in decreased expression of TAF1C mRNA CTD PMID:12002526 NCBI chr19:47,652,451...47,658,971
Ensembl chr19:47,652,452...47,658,971
JBrowse link
G Tcf12 transcription factor 12 increases expression ISO Ellagic Acid results in increased expression of TCF12 mRNA CTD PMID:12002526 NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201
JBrowse link
G Tert telomerase reverse transcriptase multiple interactions
increases expression
ISO
EXP
Ellagic Acid inhibits the reaction [Estradiol results in increased expression of TERT mRNA alternative form]
Ellagic Acid inhibits the reaction [phosalone results in decreased activity of TERT protein]
Ellagic Acid results in increased expression of TERT mRNA alternative form
CTD PMID:19501078 PMID:27965107 NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
JBrowse link
G Tfam transcription factor A, mitochondrial decreases expression ISO Ellagic Acid results in decreased expression of TFAM mRNA CTD PMID:12002526 NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression
multiple interactions
ISO
EXP
Ellagic Acid results in increased expression of TGFB1 mRNA
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TGFB1 protein]
CTD PMID:12002526 PMID:24877639 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of TNF mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of TNF protein] CTD PMID:21762681 PMID:24877639 PMID:27965107 PMID:28815802 PMID:29455002 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfrsf11a TNF receptor superfamily member 11A multiple interactions
affects binding
ISO Ellagic Acid inhibits the reaction [TNFSF11 protein binds to TNFRSF11A protein]
Ellagic Acid binds to TNFRSF11A protein
CTD PMID:32971123 NCBI chr13:21,928,370...21,986,719
Ensembl chr13:21,928,408...21,986,695
JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions
affects binding
ISO Ellagic Acid inhibits the reaction [TNFSF11 protein binds to TNFRSF11A protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein]
Ellagic Acid binds to TNFSF11 protein
CTD PMID:32971123 NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
JBrowse link
G Tnnt2 troponin T2, cardiac type multiple interactions EXP Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of TNNT2 protein] CTD PMID:21762681 NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
JBrowse link
G Tp53 tumor protein p53 increases expression
multiple interactions
ISO
EXP
Ellagic Acid results in increased expression of TP53 protein
Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]; pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]]
Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 protein]
CTD PMID:15735102 PMID:23554011 PMID:27965107 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Ugp2 UDP-glucose pyrophosphorylase 2 decreases expression ISO Ellagic Acid results in decreased expression of UGP2 mRNA CTD PMID:12002526 NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830
JBrowse link
G Usp4 ubiquitin specific peptidase 4 decreases expression ISO Ellagic Acid results in decreased expression of USP4 mRNA CTD PMID:12002526 NCBI chr 8:109,035,402...109,080,427
Ensembl chr 8:109,036,099...109,080,427
JBrowse link
G Wars1 tryptophanyl-tRNA synthetase 1 increases expression ISO Ellagic Acid results in increased expression of WARS1 mRNA CTD PMID:12002526 NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
JBrowse link
G Wee1 WEE1 G2 checkpoint kinase decreases expression ISO Ellagic Acid results in decreased expression of WEE1 protein CTD PMID:23554011 NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
JBrowse link
G Zbtb16 zinc finger and BTB domain containing 16 decreases expression ISO Ellagic Acid results in decreased expression of ZBTB16 mRNA CTD PMID:12002526 NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011
JBrowse link
G Zmym2 zinc finger MYM-type containing 2 increases expression ISO Ellagic Acid results in increased expression of ZMYM2 mRNA CTD PMID:12002526 NCBI chr15:31,035,783...31,108,945
Ensembl chr15:31,035,838...31,109,357
JBrowse link
isoquinoline-1,5-diol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [1,5-dihydroxyisoquinoline co-treated with Tretinoin] results in decreased expression of BCL2 protein CTD PMID:10713328 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Edn1 endothelin 1 decreases expression EXP 1,5-dihydroxyisoquinoline results in decreased expression of EDN1 mRNA; 1,5-dihydroxyisoquinoline results in decreased expression of EDN1 protein CTD PMID:12824290 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
JBrowse link
G Ednra endothelin receptor type A decreases expression EXP 1,5-dihydroxyisoquinoline results in decreased expression of EDNRA mRNA CTD PMID:12824290 NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
JBrowse link
G Ednrb endothelin receptor type B decreases expression EXP 1,5-dihydroxyisoquinoline results in decreased expression of EDNRB mRNA CTD PMID:12824290 NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
JBrowse link
G Hmgb1 high mobility group box 1 multiple interactions ISO 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased acetylation of HMGB1 protein]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of HMGB1 protein] CTD PMID:25517228 NCBI chr12:5,973,062...5,978,565
Ensembl chr12:5,901,586...5,978,565
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases activity
decreases expression
EXP
ISO
1,5-dihydroxyisoquinoline inhibits the reaction [Vancomycin results in increased expression of PARP1 protein]
1,5-dihydroxyisoquinoline results in decreased activity of PARP1 protein
1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]]
1,5-dihydroxyisoquinoline results in decreased expression of PARP1 protein
CTD PMID:12824290 PMID:19833176 PMID:25517228 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Sirt1 sirtuin 1 multiple interactions ISO 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]] CTD PMID:25517228 NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
JBrowse link
miglustat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO miglustat inhibits the reaction [ST8SIA1 protein results in increased expression of BCL2 protein] CTD PMID:11574545 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Canx calnexin multiple interactions ISO miglustat inhibits the reaction [CANX protein binds to CFTR protein mutant form] CTD PMID:18230692 NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
JBrowse link
G Cftr CF transmembrane conductance regulator multiple interactions
increases activity
ISO benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat results in increased activity of CFTR protein mutant form]; Brefeldin A inhibits the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [miglustat results in increased activity of CFTR protein mutant form]; geldanamycin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; geldanamycin promotes the reaction [miglustat results in increased activity of CFTR protein mutant form]; miglustat inhibits the reaction [CANX protein binds to CFTR protein mutant form]; miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; Thapsigargin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Thapsigargin promotes the reaction [miglustat results in increased activity of CFTR protein mutant form] CTD PMID:18230692 NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
JBrowse link
G Pawr pro-apoptotic WT1 regulator multiple interactions ISO miglustat inhibits the reaction [[ST8SIA1 protein affects the abundance of Gangliosides] which results in decreased expression of PAWR protein] CTD PMID:11574545 NCBI chr 7:43,645,028...43,725,033
Ensembl chr 7:43,645,084...43,725,028
JBrowse link
G St8sia1 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 multiple interactions ISO miglustat inhibits the reaction [[ST8SIA1 protein affects the abundance of Gangliosides] which results in decreased expression of PAWR protein]; miglustat inhibits the reaction [ST8SIA1 protein results in increased expression of BCL2 protein] CTD PMID:11574545 NCBI chr 4:175,782,989...175,921,338
Ensembl chr 4:175,789,947...175,920,708
JBrowse link
G Ugcg UDP-glucose ceramide glucosyltransferase multiple interactions ISO [miglustat results in decreased activity of UGCG protein] which results in decreased abundance of Gangliosides; [miglustat results in decreased activity of UGCG protein] which results in decreased abundance of Glucosylceramides CTD PMID:10037475 NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393
JBrowse link
N-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions
ISO IDH2 protein mutant form results in increased abundance of N-methylnicotinamide
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of N-methylnicotinamide]
CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance ISO SLCO1A4 protein affects the abundance of N-methylnicotinamide CTD PMID:21561886 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
JBrowse link
N-ribosylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions ISO nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate]; nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD] CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions
increases oxidation
ISO [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of 2,6-Dichloroindophenol; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q1; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]
NQO2 protein results in increased oxidation of nicotinamide-beta-riboside; NQO2 protein results in increased oxidation of nicotinamide-beta-riboside metabolite
CTD PMID:20399199 PMID:29281794 NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320
JBrowse link
nicorandil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc9 ATP binding cassette subfamily C member 9 increases activity ISO Nicorandil results in increased activity of ABCC9 protein CTD PMID:22622455 NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
JBrowse link
G Agt angiotensinogen multiple interactions ISO Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein] CTD PMID:22622455 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Alb albumin multiple interactions ISO Nicorandil inhibits the reaction [Folic Acid results in decreased expression of ALB protein] CTD PMID:33404076 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP
ISO
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of BAX protein]
Nicorandil inhibits the reaction [Folic Acid results in increased expression of BAX protein]
CTD PMID:31376360 PMID:33404076 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] CTD PMID:31376360 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Casp3 caspase 3 multiple interactions ISO Nicorandil inhibits the reaction [Folic Acid results in increased expression of CASP3 protein] CTD PMID:33404076 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cat catalase multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of CAT protein] CTD PMID:31376360 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ctsd cathepsin D multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of CTSD protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] CTD PMID:11829124 PMID:14499179 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
JBrowse link
G Gal galanin and GMAP prepropeptide multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GAL protein] CTD PMID:11829124 PMID:14499179 NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
JBrowse link
G Gusb glucuronidase, beta multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] CTD PMID:11829124 PMID:14499179 NCBI chr12:26,701,191...26,714,718
Ensembl chr12:26,697,951...26,726,905
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] CTD PMID:31376360 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
JBrowse link
G Hmox1 heme oxygenase 1 decreases expression EXP Nicorandil results in decreased expression of HMOX1 protein CTD PMID:22622455 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of IL1B protein] CTD PMID:31376360 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 multiple interactions ISO Nicorandil inhibits the reaction [Folic Acid results in increased expression of IL6 protein] CTD PMID:33404076 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Mpo myeloperoxidase multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of MPO protein] CTD PMID:31376360 NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein] CTD PMID:31376360 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of NFKB1 protein] CTD PMID:31376360 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO Nicorandil inhibits the reaction [Folic Acid results in increased expression of NOS2 protein] CTD PMID:33404076 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions ISO Nicorandil inhibits the reaction [Folic Acid results in decreased expression of NOS3 protein] CTD PMID:33404076 NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP Nicorandil results in increased expression of SOD2 protein CTD PMID:22622455 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TLR4 protein] CTD PMID:31376360 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP
ISO
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TNF protein]
Nicorandil inhibits the reaction [Folic Acid results in increased expression of TNF protein]
CTD PMID:31376360 PMID:33404076 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Xdh xanthine dehydrogenase multiple interactions
decreases expression
ISO
EXP
Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein]
Nicorandil results in decreased expression of XDH protein
CTD PMID:22622455 NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
JBrowse link
nicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acaca acetyl-CoA carboxylase alpha multiple interactions
decreases phosphorylation
ISO
EXP
Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of ACACA protein]
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]
Niacinamide results in decreased phosphorylation of ACACA protein
CTD PMID:18482975 PMID:19071085 PMID:21212096 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases secretion
multiple interactions
ISO
EXP
Niacinamide results in increased secretion of ADIPOQ protein
[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein]
CTD PMID:17452443 PMID:21439372 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Ago2 argonaute RISC catalytic component 2 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein] CTD PMID:24792773 NCBI chr 7:105,018,202...105,105,120
Ensembl chr 7:105,029,120...105,104,974
JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions EXP [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA CTD PMID:18420994 NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein] CTD PMID:25478867 NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
EXP
ISO
Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of BAX protein]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX mRNA]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX protein]
[Berberine co-treated with Niacinamide] results in increased expression of BAX protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]
Niacinamide results in increased expression of BAX mRNA; Niacinamide results in increased expression of BAX protein
CTD PMID:16168987 PMID:16998810 PMID:22164206 PMID:25478867 PMID:26712469 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA
Niacinamide results in increased expression of BBC3 mRNA
CTD PMID:26712469 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]
[Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]
CTD PMID:25472572 PMID:25478867 PMID:26712469 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein]
Niacinamide results in increased expression of BCL2L11 mRNA
CTD PMID:25472572 PMID:26712469 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Bmi1 BMI1 proto-oncogene, polycomb ring finger multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein] CTD PMID:24792773 NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
EXP
ISO
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased activity of CASP3 protein]
Niacinamide results in increased cleavage of CASP3 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; resveratrol inhibits the reaction [Niacinamide results in increased cleavage of CASP3 protein]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein]; Niacinamide promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]
CTD PMID:16505238 PMID:22164206 PMID:24040102 PMID:24962570 PMID:25478867 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions EXP
ISO
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein]
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]
CTD PMID:16505238 PMID:25478867 PMID:26712469 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cat catalase multiple interactions EXP [Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; pioglitazone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Saponins inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein] CTD PMID:20307516 PMID:21382363 PMID:21439372 PMID:21630391 PMID:22056647 More... NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Niacinamide results in decreased expression of CCL2 protein CTD PMID:14627904 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 increases expression ISO Niacinamide results in increased expression of CCL20 mRNA CTD PMID:22385246 NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
JBrowse link
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
JBrowse link
G Cd40 CD40 molecule multiple interactions ISO Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA] CTD PMID:22717288 NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
decreases expression
ISO
EXP
Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein]
Niacinamide results in increased expression of CDKN1A protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]
Niacinamide results in decreased expression of CDKN1A protein
CTD PMID:12782109 PMID:22561310 PMID:25478867 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression
multiple interactions
EXP Niacinamide results in increased expression of CDKN1B protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]
CTD PMID:22561310 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter] CTD PMID:24792773 NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases activity
multiple interactions
ISO Niacinamide results in increased activity of CHUK protein
resveratrol inhibits the reaction [Niacinamide results in increased activity of CHUK protein]
CTD PMID:24962570 NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of COL1A1 mRNA
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]
CTD PMID:16813520 PMID:25707573 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions
increases expression
EXP Clofibrate inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]; GW 6471 inhibits the reaction [Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]]; Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA] CTD PMID:23422569 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA] CTD PMID:27919644 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA] CTD PMID:27919644 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Defb5 defensin beta 5 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA CTD PMID:24894820 NCBI chr16:70,613,200...70,615,360
Ensembl chr16:70,613,146...70,615,467
JBrowse link
G Dicer1 dicer 1 ribonuclease III multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein] CTD PMID:24792773 NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965
JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; Niacinamide inhibits the reaction [geranylgeranylacetone results in increased expression of DLG1 mRNA] CTD PMID:21232033 NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689
JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein] CTD PMID:24792773 NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of EIF4EBP1 protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; Niacinamide inhibits the reaction [Resveratrol results in decreased phosphorylation of EIF4EBP1 protein]
CTD PMID:19928762 PMID:20169165 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor increases abundance
multiple interactions
ISO ERCC6 gene mutant form results in increased abundance of Niacinamide
ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased abundance of Niacinamide]
CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
G F3 coagulation factor III, tissue factor decreases expression ISO Niacinamide results in decreased expression of F3 protein CTD PMID:14627904 NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
JBrowse link
G Faslg Fas ligand multiple interactions ISO CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of FOS protein] CTD PMID:16168987 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO
EXP
Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC mRNA]; Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA]
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Niacinamide results in increased expression of and results in increased acetylation of FOXO1 protein
Niacinamide inhibits the reaction [Dexamethasone results in decreased acetylation of FOXO1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]
CTD PMID:16917544 PMID:20181797 PMID:26712469 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
JBrowse link
G Foxo3 forkhead box O3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of and results in increased expression of FOXO3 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of FOXO3 protein]; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of FOXO3 protein]; Niacinamide results in increased expression of and results in increased acetylation of FOXO3 protein CTD PMID:23022493 PMID:25472572 PMID:26712469 NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
JBrowse link
G Fth1 ferritin heavy chain 1 increases expression ISO Niacinamide results in increased expression of FTH1 mRNA; Niacinamide results in increased expression of FTH1 protein CTD PMID:23738040 NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions ISO Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC mRNA] CTD PMID:16917544 NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein] CTD PMID:19059388 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801
JBrowse link
G Gcg glucagon multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA; Sitagliptin Phosphate inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA] CTD PMID:23466488 NCBI chr 3:47,113,914...47,122,929
Ensembl chr 3:47,113,914...47,122,929
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein] CTD PMID:21439372 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions
increases expression
EXP Niacinamide inhibits the reaction [2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine inhibits the reaction [TNF protein results in increased activity of GLB1 protein]]; Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
Niacinamide results in increased expression of GLB1 protein
CTD PMID:22561310 PMID:34382399 NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
JBrowse link
G Glo1 glyoxalase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein] CTD PMID:21439372 NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP [Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of GPT protein] CTD PMID:32894639 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP [Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in decreased expression of GSR protein]; [Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein] CTD PMID:20307516 PMID:21439372 PMID:32894639 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Gstm5 glutathione S-transferase, mu 5 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA] CTD PMID:21439372 NCBI chr 2:195,531,627...195,534,562
Ensembl chr 2:195,531,495...195,534,553
JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions EXP [Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of GSTP1 protein] CTD PMID:32894639 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
G Gys2 glycogen synthase 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein] CTD PMID:19059388 NCBI chr 4:175,365,054...175,406,228
Ensembl chr 4:175,365,054...175,406,228
JBrowse link
G Hba-a2 hemoglobin alpha, adult chain 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein] CTD PMID:19647726 NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392
JBrowse link
G Hdac1 histone deacetylase 1 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein] CTD PMID:24792773 NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions EXP [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein] CTD PMID:20696151 PMID:21212096 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein] CTD PMID:21439372 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]] CTD PMID:24145604 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA CTD PMID:29594315 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA] CTD PMID:16917544 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
JBrowse link
G Il18 interleukin 18 multiple interactions EXP [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL18 mRNA CTD PMID:28322830 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression
increases expression
EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein; [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL1B mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]
Niacinamide results in decreased expression of IL1B mRNA
Niacinamide results in increased expression of IL1B mRNA
CTD PMID:20307516 PMID:21439372 PMID:22385246 PMID:28322830 PMID:29594315 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA CTD PMID:29594315 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il6 interleukin 6 decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of IL6 protein
[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]
CTD PMID:12727023 PMID:20307516 PMID:21439372 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Ins2 insulin 2 multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS protein] CTD PMID:16505238 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of JUN protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of JUN protein] CTD PMID:16168987 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein] CTD PMID:21439372 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
JBrowse link
G Klf4 Kruppel like factor 4 multiple interactions EXP [Streptozocin co-treated with Niacinamide] promotes the reaction [Dronabinol results in increased expression of KLF4 mRNA] CTD PMID:31081965 NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein] CTD PMID:20696151 NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972
JBrowse link
G Lpl lipoprotein lipase multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein] CTD PMID:20696151 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
JBrowse link
G Mafa MAF bZIP transcription factor A multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]] CTD PMID:16505238 NCBI chr 7:107,432,292...107,435,061
Ensembl chr 7:107,433,605...107,434,690
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form] CTD PMID:24145604 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of MAPK8 protein] CTD PMID:16168987 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression ISO Niacinamide results in increased expression of MDM2 mRNA CTD PMID:16998810 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
JBrowse link
G Mir3545 microRNA 3545 multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter] CTD PMID:24792773 NCBI chr 6:131,199,542...131,199,656
Ensembl chr 6:131,199,542...131,199,656
JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression
multiple interactions
ISO Niacinamide results in increased expression of MMP9 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of MMP9 protein]
CTD PMID:24145604 PMID:24962570 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Msra methionine sulfoxide reductase A multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in increased expression of MSRA protein] CTD PMID:23022493 NCBI chr15:38,363,459...38,677,406
Ensembl chr15:38,351,445...38,676,585
JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I increases expression ISO Niacinamide results in increased expression of COX1 mRNA; Niacinamide results in increased expression of COX1 protein CTD PMID:23738040 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
JBrowse link
G Mtor mechanistic target of rapamycin kinase increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of MTOR protein
Niacinamide inhibits the reaction [resveratrol results in decreased phosphorylation of MTOR protein]
CTD PMID:19928762 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in increased expression of and results in increased localization of MYC protein] CTD PMID:22028816 PMID:24792773 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Nabp2 nucleic acid binding protein 2 decreases ubiquitination
increases acetylation
multiple interactions
ISO Niacinamide results in decreased ubiquitination of NABP2 protein
Niacinamide results in increased acetylation of NABP2 protein
Niacinamide promotes the reaction [trichostatin A results in decreased ubiquitination of NABP2 protein]; Niacinamide promotes the reaction [trichostatin A results in increased acetylation of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in decreased ubiquitination of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in increased acetylation of NABP2 protein]
CTD PMID:26170237 NCBI chr 7:830,949...836,551
Ensembl chr 7:830,949...838,027
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of NAMPT protein
Niacinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA]
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein
CTD PMID:26712469 PMID:32298659 NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
JBrowse link
G Ncor1 nuclear receptor co-repressor 1 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of NCOR1 protein
Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]
CTD PMID:22539994 NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
JBrowse link
G Ndufa1 NADH:ubiquinone oxidoreductase subunit A1 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA1 mRNA] CTD PMID:23891692 NCBI chr  X:116,424,223...116,427,875
Ensembl chr  X:116,424,223...116,428,633
JBrowse link
G Ndufa13 NADH:ubiquinone oxidoreductase subunit A13 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 mRNA]; Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 protein] CTD PMID:23891692 NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
JBrowse link
G Ndufa2 NADH:ubiquinone oxidoreductase subunit A2 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA2 mRNA] CTD PMID:23891692 NCBI chr18:28,355,774...28,357,863
Ensembl chr18:28,355,774...28,358,076
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein] CTD PMID:21439372 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions EXP [Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of NFKB1 mRNA] CTD PMID:32894639 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 mRNA]; Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 protein] CTD PMID:23735732 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions
increases expression
EXP GW 6471 inhibits the reaction [resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA] CTD PMID:23422569 NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions ISO [Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA CTD PMID:20505214 NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
JBrowse link
G Ogdh oxoglutarate dehydrogenase multiple interactions ISO Niacinamide inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of OGDH protein] CTD PMID:18381761 NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases expression
increases cleavage
decreases activity
EXP
ISO
Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of PARP1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased cleavage of PARP1 protein]
Niacinamide results in increased expression of PARP1 mRNA; Niacinamide results in increased expression of PARP1 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein
Niacinamide results in increased cleavage of PARP1 protein
Niacinamide results in decreased activity of PARP1 protein
CTD PMID:16168987 PMID:19288225 PMID:22164206 PMID:26712469 PMID:29143419 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pdk4 pyruvate dehydrogenase kinase 4 multiple interactions EXP Niacinamide inhibits the reaction [Dexamethasone results in increased expression of PDK4 protein] CTD PMID:20181797 NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
JBrowse link
G Pdp1 pyruvate dehydrogenase phosphatase catalytic subunit 1 multiple interactions EXP Niacinamide inhibits the reaction [Dexamethasone results in increased phosphorylation of PDP1 protein] CTD PMID:20181797 NCBI chr 5:25,446,843...25,455,107
Ensembl chr 5:25,446,272...25,455,217
JBrowse link
G Pitx2 paired-like homeodomain 2 increases expression ISO Niacinamide results in increased expression of PITX2 mRNA; Niacinamide results in increased expression of PITX2 protein CTD PMID:29143419 NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293
JBrowse link
G Pmp22 peripheral myelin protein 22 multiple interactions ISO Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of and results in decreased localization of PMP22 protein] CTD PMID:22028816 NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
increases expression
ISO Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PPARG protein] CTD PMID:22539994 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases acetylation
multiple interactions
ISO
EXP
Niacinamide results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]
CTD PMID:19071085 PMID:23422569 PMID:23891692 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA1 protein] CTD PMID:18482975 NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
JBrowse link
G Prkaa2 protein kinase AMP-activated catalytic subunit alpha 2 multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA2 protein] CTD PMID:18482975 NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Niacinamide results in increased expression of PTGS2 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PTGS2 protein]
CTD PMID:24145604 PMID:24962570 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Pygl glycogen phosphorylase L multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] CTD PMID:19059388 NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]; Niacinamide inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Metformin inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Salicylic Acid inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]
Niacinamide results in increased acetylation of and results in increased phosphorylation of RELA protein; resveratrol inhibits the reaction [Niacinamide results in increased phosphorylation of and results in increased acetylation of RELA protein]
Niacinamide inhibits the reaction [resveratrol results in decreased expression of RELA protein modified form]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]
CTD PMID:20307516 PMID:21439372 PMID:22717288 PMID:23406761 PMID:23735732 More... NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein CTD PMID:20169165 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Runx2 RUNX family transcription factor 2 decreases expression
multiple interactions
increases expression
ISO
EXP
Niacinamide results in decreased expression of RUNX2 mRNA; Niacinamide results in decreased expression of RUNX2 protein
resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein]
Niacinamide results in increased expression of RUNX2 mRNA
CTD PMID:16813520 PMID:22539994 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
JBrowse link
G Shc1 SHC adaptor protein 1 multiple interactions
increases expression
ISO Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of SHC1 protein]
Niacinamide results in increased expression of SHC1 mRNA; Niacinamide results in increased expression of SHC1 protein
CTD PMID:21778425 PMID:24557422 NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
decreases activity
ISO
EXP
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol; Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA]
Niacinamide results in decreased expression of SIRT1 protein
[Niacinamide co-treated with Resveratrol] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Glucose]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to AICA ribonucleotide; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Fructose; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Metformin; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Resveratrol; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Salicylic Acid; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA; [Resveratrol co-treated with Niacinamide] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of and results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]; Niacinamide inhibits the reaction [Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 mRNA]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]
Niacinamide results in decreased expression of SIRT1 mRNA; Niacinamide results in decreased expression of SIRT1 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of CXCL8 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased susceptibility to Hydrogen Peroxide; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]]; Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]
CTD PMID:16366736 PMID:17103016 PMID:18420994 PMID:18482975 PMID:18681908 More... NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
JBrowse link
G Sirt2 sirtuin 2 decreases activity
multiple interactions
ISO Niacinamide results in decreased activity of SIRT2 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein
CTD PMID:17341628 PMID:26712469 NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
JBrowse link
G Sirt3 sirtuin 3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein CTD PMID:26712469 NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in decreased expression of SLC2A4 mRNA] CTD PMID:32298659 NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance ISO SLCO1A4 protein affects the abundance of Niacinamide CTD PMID:21561886 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
JBrowse link
G Snap23 synaptosome associated protein 23 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA] CTD PMID:25999625 NCBI chr 3:107,514,088...107,546,177
Ensembl chr 3:107,514,131...107,544,320
JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein; Dronabinol promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein] CTD PMID:31081965 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions EXP
ISO
Niacinamide inhibits the reaction [resveratrol results in increased expression of SOD2 mRNA]
Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SOD2 protein]
CTD PMID:23891692 PMID:25472572 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Sox9 SRY-box transcription factor 9 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of SOX9 protein
4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]; resveratrol inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]
CTD PMID:24962570 NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein] CTD PMID:24238063 NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO Niacinamide inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]] CTD PMID:23319015 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Stx4 syntaxin 4 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA] CTD PMID:25999625 NCBI chr 1:182,451,108...182,459,701
Ensembl chr 1:182,451,117...182,459,979
JBrowse link
G Tert telomerase reverse transcriptase multiple interactions EXP Niacinamide inhibits the reaction [2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine inhibits the reaction [TNF protein results in decreased activity of TERT protein]] CTD PMID:34382399 NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
JBrowse link
G Tgfb2 transforming growth factor, beta 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Niacinamide inhibits the reaction [2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine inhibits the reaction [TNF protein results in decreased activity of TERT protein]]; Niacinamide inhibits the reaction [2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine inhibits the reaction [TNF protein results in increased acetylation of TP53 protein]]; Niacinamide inhibits the reaction [2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine inhibits the reaction [TNF protein results in increased activity of GLB1 protein]]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]
Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]
Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]; Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA]
Niacinamide results in increased expression of TNF mRNA
CTD PMID:20307516 PMID:21439372 PMID:22385246 PMID:22717288 PMID:24145604 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B decreases expression ISO Niacinamide results in decreased expression of TNFRSF11B mRNA CTD PMID:16813520 NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
JBrowse link
G Tnfsf11 TNF superfamily member 11 decreases expression ISO Niacinamide results in decreased expression of TNFSF11 mRNA CTD PMID:16813520 NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases expression
ISO
EXP
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]; Niacinamide results in increased phosphorylation of and results in increased acetylation of TP53 protein
Niacinamide inhibits the reaction [2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine inhibits the reaction [TNF protein results in increased acetylation of TP53 protein]]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]
Niacinamide results in decreased expression of TP53 protein
CTD PMID:12782109 PMID:18482975 PMID:18681908 PMID:25478867 PMID:26712469 More... NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Tyr tyrosinase increases expression ISO Niacinamide results in increased expression of TYR mRNA; Niacinamide results in increased expression of TYR protein CTD PMID:23738040 NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
JBrowse link
G Ucp2 uncoupling protein 2 multiple interactions ISO Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA] CTD PMID:16366736 NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
JBrowse link
G Vamp2 vesicle-associated membrane protein 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA] CTD PMID:25999625 NCBI chr10:53,793,581...53,797,815
Ensembl chr10:53,793,923...53,797,809
JBrowse link
niraparib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO niraparib binds to and results in decreased activity of PARP1 protein CTD PMID:28001384 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Parp2 poly (ADP-ribose) polymerase 2 multiple interactions ISO niraparib binds to and results in decreased activity of PARP2 protein CTD PMID:28001384 NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
JBrowse link
NU 1025 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions
affects response to substance
ISO NU 1025 inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]
ERCC6 gene mutant form affects the susceptibility to NU 1025
CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
olaparib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acaca acetyl-CoA carboxylase alpha multiple interactions ISO [Dietary Fats co-treated with olaparib] results in decreased expression of ACACA mRNA CTD PMID:27984176 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
JBrowse link
G Acacb acetyl-CoA carboxylase beta multiple interactions ISO [Dietary Fats co-treated with olaparib] results in decreased expression of ACACB mRNA CTD PMID:27984176 NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
JBrowse link
G Acox1 acyl-CoA oxidase 1 multiple interactions ISO [Dietary Fats co-treated with olaparib] results in decreased expression of ACOX1 mRNA CTD PMID:27984176 NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACTA2 mRNA] CTD PMID:27984176 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Adgre1 adhesion G protein-coupled receptor E1 multiple interactions ISO olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ADGRE1 mRNA] CTD PMID:27984176 NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO olaparib promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]; olaparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein] CTD PMID:30296409 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Bap1 Brca1 associated protein 1 increases response to substance ISO BAP1 gene mutant form results in increased susceptibility to olaparib CTD PMID:22683710 NCBI chr16:6,446,709...6,455,535
Ensembl chr16:6,446,709...6,455,535
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO olaparib results in decreased expression of BCL2 protein CTD PMID:25531448 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO olaparib results in decreased expression of BIRC5 protein CTD PMID:25531448 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Brca1 BRCA1, DNA repair associated affects response to substance ISO BRCA1 affects the susceptibility to olaparib CTD PMID:21633166 NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
JBrowse link
G Brca2 BRCA2, DNA repair associated affects response to substance ISO BRCA2 affects the susceptibility to olaparib CTD PMID:21633166 NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [Fluorouracil co-treated with olaparib] results in increased cleavage of CASP3 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP3 protein]; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein] CTD PMID:25531448 PMID:26544897 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp8 caspase 8 multiple interactions ISO [Fluorouracil co-treated with olaparib] results in increased cleavage of CASP8 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP8 protein]; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein] CTD PMID:25531448 PMID:26544897 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein CTD PMID:25531448 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO olaparib inhibits the reaction [Ethanol results in increased expression of CCL2 protein] CTD PMID:29317476 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCN2 mRNA] CTD PMID:27984176 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of CCR2 mRNA CTD PMID:27984176 NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
JBrowse link
G Chek1 checkpoint kinase 1 increases phosphorylation ISO olaparib results in increased phosphorylation of CHEK1 protein CTD PMID:25531448 NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A1 mRNA] CTD PMID:27984176 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Ctcf CCCTC-binding factor decreases binding ISO olaparib decreases binding of CTCF to Cp promoter region in human lymphoblastoid cell lines RGD PMID:29976663 RGD:151356754 NCBI chr19:33,521,726...33,571,124
Ensembl chr19:33,529,319...33,571,123
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of CXCL2 mRNA; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CXCL2 mRNA] CTD PMID:27984176 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
ISO DDIT3 protein affects the reaction [[TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein]
olaparib results in increased expression of DDIT3 protein
CTD PMID:25531448 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO [Dietary Fats co-treated with olaparib] results in decreased expression of FASN mRNA CTD PMID:27984176 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
JBrowse link
G Fh fumarate hydratase increases response to substance ISO FH mutant form results in increased susceptibility to olaparib CTD PMID:30013182 NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of GPT protein; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of GPT protein] CTD PMID:27984176 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G H2ax H2A.X variant histone multiple interactions
increases phosphorylation
ISO [Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]; TP53 gene mutant form affects the reaction [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]]
olaparib results in increased phosphorylation of H2AX protein
CTD PMID:25531448 PMID:26544897 NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Hmgb1 high mobility group box 1 multiple interactions EXP olaparib inhibits the reaction [Ethanol results in increased expression of HMGB1 protein] CTD PMID:29339456 NCBI chr12:5,973,062...5,978,565
Ensembl chr12:5,901,586...5,978,565
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of ICAM1 mRNA CTD PMID:27984176 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of IL1B mRNA CTD PMID:27984176 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 multiple interactions ISO olaparib inhibits the reaction [Ethanol results in increased expression of IL6 protein] CTD PMID:29317476 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO Chloroquine promotes the reaction [olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; olaparib promotes the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein] CTD PMID:34826546 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Mlh1 mutL homolog 1 multiple interactions ISO olaparib inhibits the reaction [MLH1 protein results in decreased susceptibility to Floxuridine] CTD PMID:22194930 NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of MPO protein CTD PMID:27984176 NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Msh2 mutS homolog 2 multiple interactions ISO olaparib inhibits the reaction [MSH2 protein results in decreased susceptibility to Floxuridine] CTD PMID:22194930 NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
JBrowse link
G Msh3 mutS homolog 3 decreases response to substance ISO MSH3 protein results in decreased susceptibility to olaparib CTD PMID:21285347 NCBI chr 2:23,444,326...23,585,777 JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases activity
decreases binding
ISO olaparib inhibits the reaction [Hydrogen Peroxide results in increased activity of PARP1 protein]
olaparib results in decreased activity of PARP1 protein
olaparib decreases binding of PARP1 to Cp promoter region in human lymphoblastoid cell lines
CTD
RGD
PMID:24814482 PMID:28001384 PMID:29976663 RGD:151356754 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Parp2 poly (ADP-ribose) polymerase 2 multiple interactions ISO olaparib binds to and results in decreased activity of PARP2 protein CTD PMID:28001384 NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
JBrowse link
G Pla2g2a phospholipase A2 group IIA multiple interactions EXP olaparib inhibits the reaction [Ethanol results in increased expression of PLA2G2A protein] CTD PMID:29339456 NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
JBrowse link
G Pla2g4a phospholipase A2 group IVA multiple interactions EXP olaparib inhibits the reaction [Ethanol results in increased expression of PLA2G4A protein] CTD PMID:29339456 NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO [Dietary Fats co-treated with olaparib] results in decreased expression of PPARA mRNA CTD PMID:27984176 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Sdhb succinate dehydrogenase complex iron sulfur subunit B increases response to substance ISO SDHB mutant form results in increased susceptibility to olaparib CTD PMID:30013182 NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293
JBrowse link
G Sirt1 sirtuin 1 increases expression
multiple interactions
ISO olaparib results in increased expression of SIRT1 protein
olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]
CTD PMID:34826546 NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Dietary Fats co-treated with olaparib] results in decreased expression of SREBF1 mRNA CTD PMID:27984176 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB1 mRNA] CTD PMID:27984176 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of TNF mRNA; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF mRNA]; olaparib inhibits the reaction [Ethanol results in increased expression of TNF protein] CTD PMID:27984176 PMID:29317476 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions ISO [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [[TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein] CTD PMID:25531448 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases phosphorylation
ISO [Fluorouracil co-treated with olaparib] results in increased expression of TP53 protein; TP53 gene mutant form affects the reaction [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]]
olaparib results in increased phosphorylation of TP53 protein
CTD PMID:25531448 PMID:26544897 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
phenanthridone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions ISO phenanthridone inhibits the reaction [Methylnitronitrosoguanidine results in increased localization of AIFM1 protein] CTD PMID:15589979 NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256
JBrowse link
G Casp7 caspase 7 multiple interactions ISO [eprenetapopt co-treated with phenanthridone] results in increased cleavage of CASP7 protein CTD PMID:29416738 NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [eprenetapopt co-treated with phenanthridone] results in increased cleavage of CASP9 protein CTD PMID:29416738 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO phenanthridone analog inhibits the reaction [endotoxin, Escherichia coli results in increased expression of CCL3 protein] CTD PMID:12006805 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
JBrowse link
G Cd83 CD83 molecule decreases expression ISO phenanthridone results in decreased expression of CD83 mRNA; phenanthridone results in decreased expression of CD83 protein CTD PMID:17579050 NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
JBrowse link
G Cd86 CD86 molecule decreases expression ISO phenanthridone results in decreased expression of CD86 mRNA; phenanthridone results in decreased expression of CD86 protein CTD PMID:17579050 NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO phenanthridone analog inhibits the reaction [endotoxin, Escherichia coli results in increased expression of CXCL2 protein] CTD PMID:12006805 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
JBrowse link
G H2ax H2A.X variant histone increases expression
multiple interactions
ISO phenanthridone results in increased expression of H2AX protein modified form
Acetylcysteine inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form]; TXNRD1 protein inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form]
CTD PMID:29416738 NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Ifng interferon gamma multiple interactions
decreases expression
EXP phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA]
phenanthridone results in decreased expression of IFNG mRNA
CTD PMID:12411406 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il10 interleukin 10 multiple interactions ISO phenanthridone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] CTD PMID:17579050 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Il12b interleukin 12B multiple interactions ISO phenanthridone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] CTD PMID:17579050 NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
JBrowse link
G Il1b interleukin 1 beta decreases expression EXP phenanthridone results in decreased expression of IL1B mRNA CTD PMID:12411406 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 decreases expression
multiple interactions
EXP phenanthridone results in decreased expression of IL2 mRNA
phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]
CTD PMID:12411406 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Kif18a kinesin family member 18A increases metabolic processing ISO phenanthridone results in increased metabolism of KIF18A protein CTD PMID:28209915 NCBI chr 3:95,764,388...95,824,756
Ensembl chr 3:95,764,388...95,824,582
JBrowse link
G Kifc1 kinesin family member C1 increases metabolic processing ISO phenanthridone results in increased metabolism of KIFC1 protein CTD PMID:28209915 NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105
JBrowse link
G Nos2 nitric oxide synthase 2 decreases expression EXP phenanthridone results in decreased expression of NOS2 mRNA CTD PMID:12411406 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 decreases activity
multiple interactions
EXP
ISO
phenanthridone results in decreased activity of PARP1 protein
[eprenetapopt co-treated with phenanthridone] results in increased cleavage of PARP1 protein
CTD PMID:12411406 PMID:29416738 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 decreases expression EXP phenanthridone results in decreased expression of PTGS2 mRNA CTD PMID:12411406 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression
EXP
ISO
phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA]
phenanthridone analog inhibits the reaction [endotoxin, Escherichia coli results in increased expression of TNF protein]
phenanthridone results in decreased expression of TNF mRNA
CTD PMID:12006805 PMID:12411406 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions
decreases expression
ISO TXNRD1 protein inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form]
phenanthridone results in decreased expression of TXNRD1 mRNA; phenanthridone results in decreased expression of TXNRD1 protein
CTD PMID:29416738 NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
JBrowse link
rucaparib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Casp3 caspase 3 increases expression
multiple interactions
ISO rucaparib results in increased expression of CASP3 protein
[Irinotecan co-treated with rucaparib] results in increased expression of CASP3 protein
CTD PMID:30612311 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO rucaparib inhibits the reaction [Ethanol results in increased expression of CCL2 protein] CTD PMID:29317476 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G H2ax H2A.X variant histone multiple interactions
affects expression
ISO [Irinotecan co-treated with rucaparib] results in increased expression of H2AX protein
rucaparib affects the expression of H2AX protein
CTD PMID:30612311 NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Il6 interleukin 6 multiple interactions ISO rucaparib inhibits the reaction [Ethanol results in increased expression of IL6 protein] CTD PMID:29317476 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [Irinotecan co-treated with rucaparib] results in decreased expression of MKI67 protein CTD PMID:30612311 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases expression
ISO rucaparib binds to and results in decreased activity of PARP1 protein; rucaparib inhibits the reaction [Irinotecan results in increased expression of PARP1 protein]
rucaparib results in decreased expression of PARP1 protein
CTD PMID:28001384 PMID:30612311 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Parp2 poly (ADP-ribose) polymerase 2 decreases activity ISO rucaparib results in decreased activity of PARP2 protein CTD PMID:28001384 NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [Irinotecan co-treated with rucaparib] results in decreased expression of RPS6KB1 protein CTD PMID:30612311 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO rucaparib inhibits the reaction [Ethanol results in increased expression of TNF protein] CTD PMID:29317476 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnks2 tankyrase 2 affects binding ISO rucaparib binds to TNKS2 protein CTD PMID:28001384 NCBI chr 1:234,567,888...234,621,079
Ensembl chr 1:234,567,858...234,621,079
JBrowse link
soyasaponin I term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Il1b interleukin 1 beta multiple interactions ISO soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein] CTD PMID:20923188 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 multiple interactions ISO soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein] CTD PMID:20923188 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased degradation of and results in increased phosphorylation of NFKBIA protein] CTD PMID:20923188 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased activity of NOS2 protein]; soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased secretion of NOS2 protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of NOS2 protein] CTD PMID:20923188 PMID:21397503 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of PTGS2 protein] CTD PMID:20923188 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO soyasaponin I inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] CTD PMID:20923188 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Ren renin decreases activity ISO soyasaponin I results in decreased activity of REN protein CTD PMID:19060406 PMID:20460744 NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
JBrowse link
G St3gal4 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 decreases expression ISO soyasaponin I results in decreased expression of ST3GAL4 mRNA CTD PMID:15661230 NCBI chr 8:33,415,666...33,465,365
Ensembl chr 8:33,415,671...33,524,389
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO soyasaponin I inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; soyasaponin I inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] CTD PMID:20923188 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
veliparib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A increases transport ISO ABCB1 protein results in increased transport of veliparib CTD PMID:21436403 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO veliparib promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]; veliparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein] CTD PMID:30296409 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Atm ATM serine/threonine kinase multiple interactions
increases activity
ISO veliparib results in increased phosphorylation of and results in increased activity of ATM protein
veliparib results in increased activity of ATM protein
CTD PMID:21917757 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO BAK1 protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib] CTD PMID:18376143 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO BAX protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib] CTD PMID:18376143 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO BCL2L1 protein results in decreased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib] CTD PMID:18376143 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Brca1 BRCA1, DNA repair associated affects response to substance
decreases response to substance
ISO BRCA1 affects the susceptibility to veliparib
BRCA1 protein results in decreased susceptibility to veliparib
CTD PMID:21633166 PMID:21707865 NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
JBrowse link
G Brca2 BRCA2, DNA repair associated affects response to substance ISO BRCA2 affects the susceptibility to veliparib CTD PMID:21633166 NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
JBrowse link
G Cdk12 cyclin-dependent kinase 12 affects response to substance ISO CDK12 protein affects the susceptibility to veliparib CTD PMID:27880910 NCBI chr10:83,201,177...83,256,906
NCBI chr10:83,267,332...83,280,881
Ensembl chr10:83,201,211...83,280,888
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases metabolic processing ISO CYP1A2 protein results in increased metabolism of veliparib CTD PMID:21436403 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 increases metabolic processing ISO CYP2C19 protein results in increased metabolism of veliparib CTD PMID:21436403 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 increases metabolic processing ISO CYP2D6 protein results in increased metabolism of veliparib CTD PMID:21436403 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases metabolic processing ISO CYP3A4 protein results in increased metabolism of veliparib CTD PMID:21436403 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Egfr epidermal growth factor receptor decreases response to substance
affects localization
ISO EGFR protein results in decreased susceptibility to veliparib
veliparib affects the localization of EGFR protein
CTD PMID:21719137 PMID:21912620 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions ISO ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] CTD PMID:21227924 NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit multiple interactions ISO ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] CTD PMID:21227924 NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions ISO veliparib promotes the reaction [ERCC6 protein affects the susceptibility to potassium bromate] CTD PMID:25136123 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
G H2ax H2A.X variant histone multiple interactions
increases expression
ISO [veliparib co-treated with Topotecan] results in increased expression of H2AX protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]
[veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein modified form
CTD PMID:17505006 PMID:21227924 PMID:21795476 PMID:21917757 PMID:27694308 NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA] CTD PMID:27444121 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Mpg N-methylpurine-DNA glycosylase multiple interactions ISO MPG protein promotes the reaction [veliparib results in increased susceptibility to temozolomide] CTD PMID:21377995 NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520
JBrowse link
G Mre11 MRE11 homolog, double strand break repair nuclease decreases response to substance ISO MRE11 protein results in decreased susceptibility to veliparib CTD PMID:21300766 NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA] CTD PMID:27444121 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases activity
increases expression
ISO PARP1 protein affects the susceptibility to [Temozolomide co-treated with veliparib]; veliparib binds to and results in decreased activity of PARP1 protein; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form]
veliparib results in decreased activity of PARP1 protein
[veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of PARP1 protein; veliparib results in increased expression of PARP1 protein mutant form
[veliparib results in decreased activity of PARP1 protein] which results in increased susceptibility to Camptothecin
CTD PMID:17505006 PMID:19143569 PMID:19823047 PMID:19825992 PMID:21300766 More... NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Parp10 poly (ADP-ribose) polymerase family, member 10 affects binding ISO veliparib binds to PARP10 protein CTD PMID:28001384 NCBI chr 7:107,949,031...107,958,377
Ensembl chr 7:107,949,043...107,958,304
JBrowse link
G Parp2 poly (ADP-ribose) polymerase 2 affects binding
multiple interactions
decreases activity
ISO PARP2 protein binds to veliparib
veliparib binds to and results in decreased activity of PARP2 protein
veliparib results in decreased activity of PARP2 protein
CTD PMID:19143569 PMID:20092359 PMID:21917757 PMID:28001384 NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
JBrowse link
G Pten phosphatase and tensin homolog decreases response to substance ISO PTEN protein results in decreased susceptibility to veliparib CTD PMID:20530668 NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
JBrowse link
G Rpa2 replication protein A2 multiple interactions ISO veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form] CTD PMID:27694308 NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350
JBrowse link
G S100b S100 calcium binding protein B multiple interactions ISO veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA]; veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA] CTD PMID:27444121 NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
JBrowse link
G Tdp1 tyrosyl-DNA phosphodiesterase 1 multiple interactions ISO TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] CTD PMID:21227924 NCBI chr 6:119,163,192...119,231,029
Ensembl chr 6:119,163,166...119,231,021
JBrowse link
XAV939 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2m alpha-2-macroglobulin multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA CTD PMID:34480604 NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA CTD PMID:34480604 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
JBrowse link
G Acsl5 acyl-CoA synthetase long-chain family member 5 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA CTD PMID:34480604 NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
JBrowse link
G Actn2 actinin alpha 2 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACTN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA CTD PMID:34480604 NCBI chr17:58,143,334...58,210,622
Ensembl chr17:58,142,625...58,210,622
JBrowse link
G Afp alpha-fetoprotein multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA CTD PMID:34480604 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
JBrowse link
G Alb albumin multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA CTD PMID:34480604 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Aldoa aldolase, fructose-bisphosphate A multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALDOA mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA CTD PMID:34480604 NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
JBrowse link
G Amhr2 anti-Mullerian hormone receptor type 2 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA CTD PMID:34480604 NCBI chr 7:133,579,152...133,588,874
Ensembl chr 7:133,579,393...133,588,258
JBrowse link
G Anxa1 annexin A1 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA CTD PMID:34480604 NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA CTD PMID:34480604 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
JBrowse link
G Ascl1 achaete-scute family bHLH transcription factor 1 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA CTD PMID:34480604 NCBI chr 7:21,904,153...21,906,003
Ensembl chr 7:21,903,126...21,905,993
JBrowse link
G Axin2 axin 2 multiple interactions ISO XAV939 inhibits the reaction [Lithium Chloride results in increased expression of AXIN2 mRNA] CTD PMID:24534281 NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
JBrowse link
G Bmp4 bone morphogenetic protein 4 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EGLN3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GPX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HMOX1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACTN2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALDOA mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ELAVL4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FAH mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLC mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IFI44 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KEAP1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MAFG mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NEUROG2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of OLIG2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RARA mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SH3BP5 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2B mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GSTP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of KEAP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of MAFG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OLIG2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SH3BP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA CTD PMID:34480604 NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
JBrowse link
G Bmp5 bone morphogenetic protein 5 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA CTD PMID:34480604 NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
EXP XAV939 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CCND1 mRNA]; XAV939 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CCND1 protein]
XAV939 results in decreased expression of CCND1 mRNA; XAV939 results in decreased expression of CCND1 protein
CTD PMID:24231000 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO XAV939 results in decreased expression of CCND2 mRNA CTD PMID:27226553 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
JBrowse link
G Ccnd3 cyclin D3 decreases expression ISO XAV939 results in decreased expression of CCND3 mRNA CTD PMID:27226553 NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
JBrowse link
G Cdc20 cell division cycle 20 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA CTD PMID:34480604 NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
JBrowse link
G Cdh1 cadherin 1 increases expression
multiple interactions
ISO XAV939 results in increased expression of CDH1 protein
XAV939 promotes the reaction [thymoquinone results in increased expression of CDH1 protein]
CTD PMID:32112862 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
JBrowse link
G Cdh10 cadherin 10 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA CTD PMID:34480604 NCBI chr 2:68,628,623...68,850,995
Ensembl chr 2:68,628,780...68,850,995
JBrowse link
G Cdh2 cadherin 2 decreases expression
multiple interactions
ISO XAV939 results in decreased expression of CDH2 protein
XAV939 promotes the reaction [thymoquinone results in decreased expression of CDH2 protein]
CTD PMID:32112862 NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
JBrowse link
G Ceacam6 CEA cell adhesion molecule 6 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA CTD PMID:34480604 NCBI chr 1:80,416,531...80,434,668
Ensembl chr 1:80,416,531...80,434,668
JBrowse link
G Cidec cell death-inducing DFFA-like effector c multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA CTD PMID:34480604 NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA CTD PMID:34480604 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
JBrowse link
G Cryab crystallin, alpha B multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA CTD PMID:34480604 NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
decreases expression
ISO
EXP
XAV939 inhibits the reaction [CTNNB1 protein binds to CTNNBIP1 protein]; XAV939 inhibits the reaction [KIF23 protein results in increased expression of CTNNB1 protein]; XAV939 inhibits the reaction [Lithium Chloride affects the localization of CTNNB1 protein]; XAV939 inhibits the reaction [TMED3 protein results in increased expression of CTNNB1 protein]; XAV939 promotes the reaction [thymoquinone results in decreased expression of and results in increased phosphorylation of CTNNB1 protein]; XAV939 results in decreased expression of and results in increased phosphorylation of CTNNB1 protein
XAV939 results in decreased expression of CTNNB1 mRNA
XAV939 results in decreased expression of CTNNB1 protein
XAV939 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CTNNB1 protein]
CTD PMID:24231000 PMID:24534281 PMID:25061499 PMID:27226553 PMID:32112862 More... NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Ctnnbip1 catenin, beta-interacting protein 1 multiple interactions ISO XAV939 inhibits the reaction [CTNNB1 protein binds to CTNNBIP1 protein] CTD PMID:24534281 NCBI chr 5:159,961,961...160,010,942
Ensembl chr 5:159,961,928...160,010,939
JBrowse link
G Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA CTD PMID:34480604 NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
JBrowse link
G Cyp26b1 cytochrome P450, family 26, subfamily b, polypeptide 1 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA CTD PMID:34480604 NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA CTD PMID:34480604 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
JBrowse link
G Dcc DCC netrin 1 receptor multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA CTD PMID:34480604 NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740
JBrowse link
G Dcn decorin multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA CTD PMID:34480604 NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
JBrowse link
G Dcx doublecortin multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA CTD PMID:34480604 NCBI chr  X:107,430,767...107,573,612
Ensembl chr  X:107,430,767...107,507,476
JBrowse link
G Dhrs9 dehydrogenase/reductase 9 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA CTD PMID:34480604 NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA CTD PMID:34480604 NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458
JBrowse link
G Ebf1 EBF transcription factor 1 decreases expression ISO XAV939 results in decreased expression of EBF1 mRNA CTD PMID:27226553 NCBI chr10:29,095,858...29,489,142
Ensembl chr10:29,099,933...29,487,665
JBrowse link
G Ebf3 EBF transcription factor 3 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA CTD PMID:34480604 NCBI chr 1:191,996,726...192,114,713
Ensembl chr 1:191,996,730...192,114,359
JBrowse link
G Ecscr endothelial cell surface expressed chemotaxis and apoptosis regulator multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA CTD PMID:34480604 NCBI chr18:27,309,711...27,319,106
Ensembl chr18:27,309,718...27,319,032
JBrowse link
G Egln3 egl-9 family hypoxia-inducible factor 3 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EGLN3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA CTD PMID:34480604 NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
JBrowse link
G Elavl3 ELAV like RNA binding protein 3 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA CTD PMID:34480604 NCBI chr 8:20,547,108...20,583,369
Ensembl chr 8:20,550,201...20,583,641
JBrowse link
G Elavl4 ELAV like RNA binding protein 4 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ELAVL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA CTD PMID:34480604 NCBI chr 5:125,056,848...125,200,543
Ensembl chr 5:125,056,848...125,200,446
JBrowse link
G Emx2 empty spiracles homeobox 2 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA CTD PMID:34480604 NCBI chr 1:258,626,584...258,633,594
Ensembl chr 1:258,626,584...258,633,594
JBrowse link
G Fabp1 fatty acid binding protein 1 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA CTD PMID:34480604 NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
JBrowse link
G Fah fumarylacetoacetate hydrolase multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FAH mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA CTD PMID:34480604 NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505
JBrowse link
G Fbxo32 F-box protein 32 multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA CTD PMID:34480604 NCBI chr 7:89,731,626...89,764,761
Ensembl chr 7:89,730,232...89,765,436
JBrowse link
G Fgb fibrinogen beta chain multiple interactions ISO [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA CTD PMID:34480604 NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
JBrowse link
G Fgf1 fibroblast growth factor 1 multiple interactions ISO [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ABCC1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ACTN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ALDOA mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ASCL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CDC20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of CYP24A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of DCX mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ECSCR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ELAVL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of EMX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of ESRG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FAH mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FLT1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXD3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of FOXG1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of GSTP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of H2BC14 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of HES5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of KEAP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of LCK mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of MAFG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OLIG2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of OTX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of POU5F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SFRP2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SH3BP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SOX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SPTSSB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of SRXN1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in decreased expression of STMN2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of A2M mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ACSL5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AFP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ALB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of AMHR2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ANXA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of APOA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of BMP5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CDH10 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CEACAM6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CIDEC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of COL3A1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CRYAB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP26B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCC mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DCN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DHRS9 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of DNAJB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EBF3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of EGLN3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FABP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FBXO32 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGB mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGF7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FGG mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of FLRT3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GADD45A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GATA6 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GCLM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPR183 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GPX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GSTO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GUCY1A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAND2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HAVCR1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HMGCS2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXA2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXB3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HOXD8 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of HSD3B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGFBP7 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IGHV3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of IL1R1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ISL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of KRT6A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LEF1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of LUM mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MLIP mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MMP1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MPZL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of MYL4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NQO1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of NR2F2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PDE1A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of PLN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RBM20 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of RRAD mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCARB1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SCN2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SEMA3C mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SERPINA1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SLCO2B1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of SQSTM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TBX2 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TF mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TFAP2A mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TM4SF4 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TTR mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of TXNRD1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of UGT2A3 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VCAM1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VGLL1 mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of VTN mRNA; [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of ZFAND2A mRNA CTD